Borgen P - Search Results

1

Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.

Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. Traina TA, et al. Among authors: borgen p. Breast Cancer Res Treat. 2008 Sep;111(2):377-88. doi: 10.1007/s10549-007-9787-1. Epub 2007 Oct 20. Breast Cancer Res Treat. 2008. PMID: 17952589 Clinical Trial.

2

Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma.

Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP. Youngson BJ, et al. Among authors: borgen pi. Am J Surg Pathol. 1995 Dec;19(12):1354-8. doi: 10.1097/00000478-199512000-00002. Am J Surg Pathol. 1995. PMID: 7503357

3

p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Rosen PP, et al. Among authors: borgen p. J Clin Oncol. 1995 Apr;13(4):821-30. doi: 10.1200/JCO.1995.13.4.821. J Clin Oncol. 1995. PMID: 7707107

4

Mutations of the p53 gene in male breast cancer.

Anelli A, Anelli TF, Youngson B, Rosen PP, Borgen PI. Anelli A, et al. Among authors: borgen pi. Cancer. 1995 May 1;75(9):2233-8. doi: 10.1002/1097-0142(19950501)75:9<2233::aid-cncr2820750907>3.0.co;2-s. Cancer. 1995. PMID: 7712430

5

Calcium glucarate as a chemopreventive agent in breast cancer.

Heerdt AS, Young CW, Borgen PI. Heerdt AS, et al. Among authors: borgen pi. Isr J Med Sci. 1995 Feb-Mar;31(2-3):101-5. Isr J Med Sci. 1995. PMID: 7744577 Review.

6

Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis.

Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. Rosen PP, et al. Among authors: borgen p. Cancer. 1995 Mar 15;75(6):1320-6. doi: 10.1002/1097-0142(19950315)75:6<1320::aid-cncr2820750614>3.0.co;2-c. Cancer. 1995. PMID: 7882282

7

Breast conservation therapy for invasive carcinoma of the breast.

Borgen PI, Heerdt AS, Moore MP, Petrek JA. Borgen PI, et al. Curr Probl Surg. 1995 Mar;32(3):191-248. doi: 10.1016/s0011-3840(05)80016-4. Curr Probl Surg. 1995. PMID: 7882704 Free article. Review. No abstract available.

8

Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.

Anelli TF, Anelli A, Tran KN, Lebwohl DE, Borgen PI. Anelli TF, et al. Among authors: borgen pi. Cancer. 1994 Jul 1;74(1):74-7. doi: 10.1002/1097-0142(19940701)74:1<74::aid-cncr2820740113>3.0.co;2-#. Cancer. 1994. PMID: 8004585

9

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.

Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K. Neuhausen S, et al. Among authors: borgen p. Nat Genet. 1996 May;13(1):126-8. doi: 10.1038/ng0596-126. Nat Genet. 1996. PMID: 8673092

10

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.

Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K. Oddoux C, et al. Among authors: borgen p. Nat Genet. 1996 Oct;14(2):188-90. doi: 10.1038/ng1096-188. Nat Genet. 1996. PMID: 8841192

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

202 results

Search Page

Filters